

Table of contents

1) Introduction-----	Page 001
2) Aims and Objectives-----	Page 005
3) Drugs studied-----	Page 011
4) Impurity profiling, degradation pathways and analytical methods-----	Page 012
Felbamate-----	Page 012
Cevimeline HCl-----	Page 115
Lenalidomide-----	Page 186
Clofarabine-----	Page 195
Saxagliptin-----	Page 286
Ambrisentan-----	Page 307
Bepotastine Besilate-----	Page 318
Conivaptan HCl-----	Page 335
5) References-----	Page 351